Jazz Pharmaceuticals plc (JAZZ)
JAZZ Stock Price Chart
Explore Jazz Pharmaceuticals plc interactive price chart. Choose custom timeframes to analyze JAZZ price movements and trends.
JAZZ Company Profile
Discover essential business fundamentals and corporate details for Jazz Pharmaceuticals plc (JAZZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jun 2007
Employees
2.89k
Website
https://www.jazzpharma.comCEO
Renee D. Gala
Description
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ Financial Timeline
Browse a chronological timeline of Jazz Pharmaceuticals plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $6.22, while revenue estimate is $1.11bn.
Earnings released on 5 May 2026
EPS came in at $6.34 surpassing the estimated $4.64 by +36.64%, while revenue for the quarter reached $1.07bn , beating expectations by +9.22%.
Earnings released on 24 Feb 2026
EPS came in at $6.64 surpassing the estimated $6.52 by +1.84%, while revenue for the quarter reached $1.20bn , beating expectations by +2.81%.
Earnings released on 5 Nov 2025
EPS came in at $8.13 surpassing the estimated $5.95 by +36.64%, while revenue for the quarter reached $1.13bn , beating expectations by +1.35%.
Earnings released on 5 Aug 2025
EPS came in at -$8.25 falling short of the estimated -$6.12 by -34.80%, while revenue for the quarter reached $1.05bn , missing expectations by -0.14%.
Earnings released on 6 May 2025
EPS came in at $1.68 falling short of the estimated $4.51 by -62.75%, while revenue for the quarter reached $897.84m , missing expectations by -15.68%.
Earnings released on 25 Feb 2025
EPS came in at $6.60 surpassing the estimated $5.83 by +13.21%, while revenue for the quarter reached $1.09bn , beating expectations by +10.48%.
Earnings released on 6 Nov 2024
EPS came in at $6.61 surpassing the estimated $5.47 by +20.84%, while revenue for the quarter reached $1.05bn , missing expectations by -0.18%.
Earnings released on 31 Jul 2024
EPS came in at $5.30 surpassing the estimated $4.68 by +13.25%, while revenue for the quarter reached $1.02bn , missing expectations by -1.34%.
Earnings released on 1 May 2024
EPS came in at $2.68 falling short of the estimated $4.14 by -35.27%, while revenue for the quarter reached $901.98m , missing expectations by -5.45%.
Earnings released on 28 Feb 2024
EPS came in at $5.02 falling short of the estimated $5.26 by -4.56%, while revenue for the quarter reached $1.01bn , beating expectations by +5.71%.
Earnings released on 8 Nov 2023
EPS came in at $4.84 falling short of the estimated $4.90 by -1.22%, while revenue for the quarter reached $972.14m , missing expectations by -3.63%.
Earnings released on 9 Aug 2023
EPS came in at $4.51 surpassing the estimated $4.46 by +1.12%, while revenue for the quarter reached $957.32m , beating expectations by +1.53%.
Earnings released on 10 May 2023
EPS came in at $3.95 falling short of the estimated $4.26 by -7.28%, while revenue for the quarter reached $892.81m , missing expectations by -5.42%.
Earnings released on 1 Mar 2023
EPS came in at -$0.07 falling short of the estimated $0.51 by -113.73%, while revenue for the quarter reached $972.12m , beating expectations by +8.57%.
Earnings released on 9 Nov 2022
EPS came in at $5.17 surpassing the estimated $4.72 by +9.53%, while revenue for the quarter reached $940.65m , beating expectations by +0.07%.
Earnings released on 3 Aug 2022
EPS came in at $4.30 surpassing the estimated $4.20 by +2.38%, while revenue for the quarter reached $932.88m , beating expectations by +3.37%.
Earnings released on 4 May 2022
EPS came in at $3.73 falling short of the estimated $3.75 by -0.53%, while revenue for the quarter reached $813.72m , missing expectations by -4.54%.
Earnings released on 1 Mar 2022
EPS came in at $4.21 surpassing the estimated $3.71 by +13.48%, while revenue for the quarter reached $896.73m , beating expectations by +3.75%.
Earnings released on 9 Nov 2021
EPS came in at $4.20 surpassing the estimated $3.27 by +28.44%, while revenue for the quarter reached $838.12m , beating expectations by +0.39%.
Earnings released on 3 Aug 2021
EPS came in at $3.90 surpassing the estimated $3.55 by +9.86%, while revenue for the quarter reached $751.81m , meeting expectations.
JAZZ Stock Performance
Access detailed JAZZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
